Clinical trial
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating…
NCT00277225 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00277225 |
|---|---|
| Title | A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris |
| Official title | A Phase I,Randomized, Double Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Psoriasis Vulgaris |
| Intervention type | Drug |
| Interventions | Abatacept |
| Enrollment | 32 |
| Start date | Nov 1, 1995 |
| Primary completion | Jun 1, 1996 |
| Completion | Jun 1, 1996 |
| First posted | Jan 16, 2006 |
| Last update posted | Apr 13, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: